Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

od of 2008 was primarily a result of the 2008 write-off of $1.9 million of deferred offering costs related to a delay in the Company's IPO. Also, in the 2009 period there were decreases in contract service costs associated with several of Omeros' clinical and preclinical programs and in clinical trial expenses due to the prior completion of enrollment in the Company's Phase 2 clinical study of OMS103HP for arthroscopic meniscectomy surgery.

Total operating expenses for the nine months ended September 30, 2009 were $16.5 million, compared to $19.1 million for the same period in 2008. The decrease in operating expenses in the nine months ended September 30, 2009 as compared to the same period of 2008 was primarily a result of items noted above.

Recent Highlights

  • Priced the Company's IPO on October 7, 2009, receiving net proceeds of approximately $61.8 million, and began trading on The NASDAQ Global Market under the ticker symbol "OMER" on October 8, 2009.
  • Announced positive results from the Phase 1/Phase 2 clinical trial of OMS302, Omeros' PharmacoSurgery product candidate being developed for use during ophthalmological procedures. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles. The Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of OMS302 added to a standard surgical irrigation solution. Data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control.
  • Amended its agreement with Patobios Limited by which Omeros has the exclusive right to acquire
    '/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
(Date:5/5/2015)... 2015   Tocagen Inc. , a clinical-stage ... Parkinson , M.D., a venture partner at New ... board of directors of Tocagen. Dr. Parkinson has ... clinical development, including leading clinical activities at Amgen ... the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and ...
(Date:5/5/2015)... Synedgen Inc. is pleased to announce ... Manager. , Dr. Nguyen brings to Synedgen critical regulatory ... company as it moves forward in the FDA regulatory ... two years. Dr. Nguyen will lead the management of ... documents that must be completed in order to initiate ...
(Date:5/4/2015)... /PRNewswire/ - JSS Medical Research Inc., a Montreal ... the acquisition of Max Neeman International (MNI), with head office in ... located in Ahmedabad, Bangalore , Chennai ... subsidiary, a regional office is located North Carolina, USA ... the recent equity investment transaction into JSS with Capital Croissance PME ...
Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4Synedgen Announces the Appointment of Regulatory Affairs Manager 2JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
... CardioInsight Technologies Inc., the leading developer of ... of Jim Bullock as Chairman of the Company,s ... ) Mr. Bullock is a ... has served as Chief Executive Officer of Atritech, ...
... a biotechnology research company and leading developer of human ... of new drug compounds, has been invited to present ... Vascular Biology (ATVB) conference .  The conference will be ... South Michigan Avenue in Chicago, Illinois. ...
... ability to control the flow of electrons using engineered ... many properties of matter are still unclear. Now a ... of the exotic electronic properties in matter using optical ... Jacob is the co-lead author on a study of ...
Cached Biology Technology:CardioInsight Announces Appointment of Jim Bullock as Chairman of the Board of Directors 2HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference 2
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... prefer to wipe the venomous little varmints off the face of ... The reviled South American native that invaded the U.S. Sun Belt ... invicta and everywhere else as a painful pest in the grass, ... ardent fire ant fan and one of its foremost researchers for ...
... Grail of horticultural accomplishment would be grass that never grows ... suburban bliss -- and more -- seems plausible as scientists ... stature of plants. In addition to lawns that rarely require ... more fruitful crop plants such as rice, wheat, soybeans, and ...
... the U.S. have their heels pricked soon after birth ... "heel stick" tests identify rare metabolic disorders before they ... to the screening ?many states now test for 30 ... the June issue of Pediatrics, researchers from Children's Hospital ...
Cached Biology News:Fire ants: Their true story told by the scientist who loves them 2Fire ants: Their true story told by the scientist who loves them 3No-mow grass may be coming to your yard soon 2No-mow grass may be coming to your yard soon 3Newborn screening can cause unnecessary parental stress 2Newborn screening can cause unnecessary parental stress 3
Request Info...
DNA polymerase I, large fragment...
supplied with 10x reaction buffer...
... overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: ... unit of HK will phosphorylate ... 1 min at 25C at ... G6P-DH will oxidize 1 mol ...
Biology Products: